• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Consumer Cyclical·CAL
Held by 2 Gurus
Share

Caleres, Inc. Stocks

$ 12.92Last Updated 26.10.2026

Issuer Rating

5/7
Performance

Strong

Risk

Considerable

Recommendation

Hold

Market Cap

$ 446.84M

$ 12.92
Key Takeaways

Risk factor

Weak & very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Steven Cohen

Portfolio Weight (%)

0.0%

Change

-0.00%

Fund

Point72 Asset Management, L.P.

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

-0.00%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Steven CohenPoint72 Asset Management, L.P.0.0%-0.00%
Kenneth GriffinCITADEL ADVISORS LLC0.0%-0.00%

Latest news

28.10.2025 09:00

S&P Global announces changes to S&P 500 and S&P SmallCap 600

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Caleres, Inc. is a long-standing company primarily involved in the design, sourcing, retail, and wholesale distribution of various footwear products. Its operations span the United States, Canada, China, and Guam, organized into two main divisions: Famous Footwear and Brand Portfolio. The company's comprehensive product range includes athletic, casual, and dress footwear available under licensed, proprietary, and private-label brands, catering to women, men, and children. Through its numerous retail shoe stores, Caleres offers customers a wide selection of popular brand-name shoes from leading manufacturers like Nike, Skechers, adidas, and Dr. Martens. This is complemented by a substantial portfolio of company-owned and licensed brands such as Dr. Scholl's Shoes, Blowfish Malibu, LifeStride, Naturalizer, Franco Sarto, and Ryka. Beyond its physical storefronts, Caleres maintains a significant digital presence, managing a multitude of brand-specific e-commerce websites including naturalizer.com, samedelman.com, allenedmonds.com, and many others. The company also plays a crucial role in the broader footwear supply chain, engaging in the design, sourcing, manufacturing, and marketing of footwear to a diverse client base. This includes national chains, online retailers, department stores, mass merchandisers, independent retailers, and catalog businesses. Its wholesale division additionally distributes men's apparel, leather goods, and accessories under the Allen Edmonds brand, as well as specialized women's footwear lines such as LifeStride, Italian footwear by Franco Sarto, athletic shoes from Rykä, and collections from Vince, Bzees, Zodiac, Veronica Beard, and Via Spiga. With approximately 980 retail locations, the company has a strong market footprint. Founded in 1878 and formerly known as Brown Shoe Company, Inc., Caleres, Inc. is headquartered in St. Louis, Missouri.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, of fair

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of CAL is 17.5 and suggests 35.1% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.10.2026 07:01

Healthcare stocks have become a bet against AI. Should you buy them?

28.10.2026 03:18

"The conditions for a rebound are ripe": Stocks rise for a second day ahead of big tech earnings reports

28.10.2026 03:13

Oracle is expanding its partnership with OpenAI and integrating Google chips into its infrastructure

28.10.2026 00:20

Memory stocks cool off in 2H26 amid AI spending doubts

27.10.2026 22:38

GM will move its listing to the Nasdaq. What does this mean for its stock?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026